Seer (NASDAQ:SEER) versus NovAccess Global (OTCMKTS:XSNX) Head to Head Contrast

Seer (NASDAQ:SEER) and NovAccess Global (OTCMKTS:XSNX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, valuation, dividends, institutional ownership and analyst recommendations.

Earnings and Valuation

This table compares Seer and NovAccess Global”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seer	$14.17 million	9.14	-$86.60 million	($1.41)	-1.56
NovAccess Global	N/A	N/A	-$4.72 million	($0.11)	N/A

NovAccess Global has lower revenue, but higher earnings than Seer. Seer is trading at a lower price-to-earnings ratio than NovAccess Global, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Seer has a beta of 1.57, suggesting that its share price is 57% more volatile than the S&P 500. Comparatively, NovAccess Global has a beta of 3.2, suggesting that its share price is 220% more volatile than the S&P 500.

Insider & Institutional Ownership

75.2% of Seer shares are held by institutional investors. 11.3% of Seer shares are held by insiders. Comparatively, 1.4% of NovAccess Global shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Seer and NovAccess Global’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Seer	-560.90%	-24.69%	-22.13%
NovAccess Global	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Seer and NovAccess Global, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seer	0	1	0	0	2.00
NovAccess Global	0	0	0	0	0.00

Seer presently has a consensus price target of $3.00, indicating a potential upside of 36.36%. Given Seer’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Seer is more favorable than NovAccess Global.

Summary

NovAccess Global beats Seer on 6 of the 11 factors compared between the two stocks.

About Seer

Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company intends to sell its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It operates in China, Australia, Eastern Europe, Israel, and Japan. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.

About NovAccess Global

NovAccess Global Inc., a biopharmaceutical company, develops novel immunotherapies to treat brain tumor patients in the United States. It specializes in cutting-edge research related to utilizing a patient’s immune system to attack the cancer. The company was incorporated in 1997 and is headquartered in Chagrin Falls, Ohio.